Oncology/Cancer Drugs Market Trends by Types and Application, Forecast Analysis

Posted by sanjayhande on December 5th, 2019

Surge in incidence of cancer across the globe and considerable rise in expenditure on healthcare services by governments facilitate the growth in the global oncology/cancer drugs market. However, fatal effects related to cancer drugs usage hinder the market growth. On the other hand, surge in number of pipeline drugs and untapped potential in emerging countries offer lucrative opportunities in the industry.

Allied Market Research published a report, titled, "Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2025." According to the report, the global oncology/cancer drugs market generated .40 billion in 2017, and is estimated to reach 6.50 billion by 2025, growing at a CAGR of 7.6% from 2018 to 2025.

Click Here To Access The Sample Report @ https://www.alliedmarketresearch.com/request-sample/121

Based on drug class type, the targeted therapy and chemotherapy segments together accounted for nearly three-fourths of the total market share in 2017, and is expected to maintain dominance in the cancer drugs industry throughout the forecast period. Contrarily, the immunotherapy segment is estimated to register the highest growth rate with a CAGR of 10.4% from 2018 to 2025, owing to higher rates of survival and remission related to their use.

Based on indication, the lung cancer segment is estimated to register the largest CAGR of 11.7% from 2018 to 2025, owing to considerable surge in prevalence across the world. On the other hand, the kidney, breast, and prostate cancer segments together contributed to two-fifths of the total market share in 2017 and is expected to continue its leadership status during the forecast period.

Based on region, Asia-Pacific is projected to grow at the highest rate, registering a CAGR of 9.5% from 2018 to 2025. This is owing to huge base of population and advanced healthcare infrastructure. North America and Europe together accounted for nearly three-fourths of the total market share in 2017, and will maintain their dominance by 2025, owing to rise in awareness regarding advanced therapies, growth in sedentary lifestyle, and ease in accessibility to premiere chemotherapy treatments.

Leading market players discussed in the research are following:

• Amgen Inc.
• Celgene Corporation
• Eli Lilly and Company
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc.
• Johnson & Johnson
• Pfizer Inc.
• Merck & Co., Inc.
• Sanofi.

Obtain Report Details: https://www.alliedmarketresearch.com/oncology-cancer-drugs-market 

About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.